牛牛AI助手已提取核心信息
Prudential Financial, Inc. has filed an amendment to its Schedule 13G with the Securities and Exchange Commission, disclosing its ownership stake in Arcutis Biotherapeutics Inc. As of December 31, 2023, Prudential Financial holds an aggregate of 9,884,137 shares of Arcutis Biotherapeutics' common stock, representing 10.47% of the company's class of securities. The filing, dated February 14, 2024, indicates that Prudential Financial has both sole and shared voting and dispositive power over a significant number of shares. The shares are beneficially owned through various subsidiaries, including Jennison Associates LLC and PGIM, Inc., among others. Prudential Financial asserts that the acquisition of these shares is in the ordinary course of business and not for the purpose of changing or influencing the control of Arcutis Biotherapeutics. The filing also clarifies that this should not be considered an admission that Prudential Financial is the beneficial owner of the shares for the purposes of Sections 13 or 16 of the Securities Exchange Act of 1934.
Prudential Financial, Inc. has filed an amendment to its Schedule 13G with the Securities and Exchange Commission, disclosing its ownership stake in Arcutis Biotherapeutics Inc. As of December 31, 2023, Prudential Financial holds an aggregate of 9,884,137 shares of Arcutis Biotherapeutics' common stock, representing 10.47% of the company's class of securities. The filing, dated February 14, 2024, indicates that Prudential Financial has both sole and shared voting and dispositive power over a significant number of shares. The shares are beneficially owned through various subsidiaries, including Jennison Associates LLC and PGIM, Inc., among others. Prudential Financial asserts that the acquisition of these shares is in the ordinary course of business and not for the purpose of changing or influencing the control of Arcutis Biotherapeutics. The filing also clarifies that this should not be considered an admission that Prudential Financial is the beneficial owner of the shares for the purposes of Sections 13 or 16 of the Securities Exchange Act of 1934.
保诚金融公司已向美国证券交易委员会提交了附表13G的修正案，披露了其在Arcutis Biotherapeutics Inc.的所有权。截至2023年12月31日，保诚金融共持有Arcutis Biotherapeutics普通股9,884,137股，占该公司证券类别的10.47％。这份日期为2024年2月14日的文件表明，保诚金融对大量股票拥有唯一和共享的投票权和处置权。这些股份由包括Jennison Associates LLC和PGIM, Inc.在内的多家子公司实益持有。保诚金融断言，收购这些股份是在正常业务过程中，不是为了改变或影响Arcutis Biotherapeutics的控制权。该文件还澄清说，就1934年《证券交易法》第13或16条而言，这不应被视为承认保诚金融是股票的受益所有人。
保诚金融公司已向美国证券交易委员会提交了附表13G的修正案，披露了其在Arcutis Biotherapeutics Inc.的所有权。截至2023年12月31日，保诚金融共持有Arcutis Biotherapeutics普通股9,884,137股，占该公司证券类别的10.47％。这份日期为2024年2月14日的文件表明，保诚金融对大量股票拥有唯一和共享的投票权和处置权。这些股份由包括Jennison Associates LLC和PGIM, Inc.在内的多家子公司实益持有。保诚金融断言，收购这些股份是在正常业务过程中，不是为了改变或影响Arcutis Biotherapeutics的控制权。该文件还澄清说，就1934年《证券交易法》第13或16条而言，这不应被视为承认保诚金融是股票的受益所有人。
有用
没用